Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Avacincaptad pegol significantly reduces progression of ellipsoid zone degradation and geographic atrophy lesion growth, highlighting its potential to preserve photoreceptor integrity in AMD patients.
In a phase 2 randomized trial, oral vemircopan did not improve clinical outcomes over placebo in AChR-antibody–positive generalized myasthenia gravis, despite a mechanistically attractive strategy to selectively inhibit the alternative comp
In the phase 3 VALIANT trial, pegcetacoplan, a C3/C3b inhibitor, produced a large, rapid reduction in proteinuria versus placebo at 26 weeks in patients with C3 glomerulopathy or primary immune‑complex MPGN, with an acceptable short-term sa
The APPEAR-C3G phase 3 trial demonstrates that oral iptacopan significantly reduces proteinuria and is well tolerated in adults with C3 glomerulopathy, an ultra-rare glomerulonephritis linked to alternative complement pathway overactivation